US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Soligenix, Inc.

1.60

+0.01000.63%

Volume:370.01K

Turnover:595.65K

Market Cap:16.14M

PE:-0.38

High:1.65

Open:1.62

Low:1.55

Close:1.59

52wk High:6.23

52wk Low:1.09

Shares:10.09M

Float Shares:7.93M

Volume Ratio:1.06

T/O Rate:4.67%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.2455

EPS(LYR):-4.9786

ROE:-165.10%

ROA:-69.38%

PB:2.12

PE(LYR):-0.32

Loading ...

Overview Company News Filings

Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

Soligenix Inc. unveils pipeline progress and rare disease treatment strategies in new corporate presentation

Soligenix completes enrollment of patients for Phase 3 study evaluating HyBryte

Soligenix Reaches Interim Enrollment Milestone in Phase 3 HyBryte Trial for CTCL

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of Hybryte™ for the Treatment of Cutaneous T-Cell Lymphoma

THOMSON REUTERS

Soligenix Regains Nasdaq Compliance After Equity Shortfall

Biopharma firm Soligenix's Q3 net loss widens on increased R&D spends

Soligenix Reports Net Loss of $2.5 Million With No Revenue in Q3 2025

Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results

THOMSON REUTERS

Soligenix Q3 EPS USD -0.58

THOMSON REUTERS

Soligenix Announces Key Safety Milestone in Phase 3 FLASH2 Trial of HyBryte™ for Cutaneous T-Cell Lymphoma; Enrollment Progress on Track

Soligenix Inc - Flash2 Study Interim Efficacy Analysis Targeted for 1H2026

THOMSON REUTERS

Soligenix Inc - Enrollment Update Remains on Track for 4Q2025

THOMSON REUTERS

Soligenix Achieves Important Safety Milestone in Its Confirmatory Phase 3 Clinical Trial of Hybryte™ for the Treatment of Cutaneous T-Cell Lymphoma

THOMSON REUTERS

Soligenix Inc. Chairman, CEO and President Christopher J. Schaber Reports Acquisition of Common Shares

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

THOMSON REUTERS

Soligenix Inc. Expands European Medical Advisory Board to Support HyBryte™ Phase 3 Trial and Regulatory Strategy

BRIEF-Soligenix Says On Sept 25, Entered Securities Purchase Agreement With Investors - SEC Filing

BRIEF-Soligenix Announces Closing Of $7.5 Million Public Offering

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SNGX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SNGX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SNGX\",,,,,undefined,":{"symbol":"SNGX","market":"US","secType":"STK","nameCN":"Soligenix, Inc.","latestPrice":1.6,"timestamp":1765400400000,"preClose":1.59,"halted":0,"volume":370013,"delay":0,"floatShares":7928900,"shares":10086130,"eps":-4.245498,"marketStatus":"Pre-Mkt","change":0.01,"latestTime":"12-11 06:32:23 EST","open":1.62,"high":1.65,"low":1.545,"amount":595646.4833844,"amplitude":0.066038,"askPrice":1.78,"askSize":200,"bidPrice":1.52,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.245498,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765463400000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.6,"postHourTrading":{"tag":"盘后","latestPrice":1.59,"preClose":1.6,"latestTime":"19:04 EST","volume":1068,"amount":1700.604,"timestamp":1765411462427},"volumeRatio":1.0592110568457036},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SNGX\",,,,,undefined,":{"symbol":"SNGX","floatShares":7928900,"roa":"-69.38%","roe":"-165.10%","lyrEps":-4.978626,"volumeRatio":1.0592110568457036,"shares":10086130,"dividePrice":0,"high":1.65,"amplitude":0.066038,"preClose":1.59,"low":1.545,"week52Low":1.09,"pbRate":"2.12","week52High":6.2299,"institutionHeld":0.088,"latestPrice":1.6,"committee":-0.333333,"eps":-4.245498,"divideRate":0,"volume":370013,"delay":0,"ttmEps":-4.245498,"open":1.62,"prevYearClose":2.695,"prevWeekClose":1.61,"prevMonthClose":1.59,"prevQuarterClose":1.16,"fiveDayClose":1.55,"twentyDayClose":1.42,"sixtyDayClose":2.79},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SNGX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-07","symbol":"SNGX","fiscalQuarterEnding":"2025/09","expectedEps":-0.63,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762491600000,"reportTimeType":"pre","actualEps":-0.58},{"market":"US","date":"2025-08-14","symbol":"SNGX","fiscalQuarterEnding":"2025/06","expectedEps":-0.79,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"pre","actualEps":-0.82},{"market":"US","date":"2025-05-09","symbol":"SNGX","fiscalQuarterEnding":"2025/03","expectedEps":-0.67,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746763200000,"reportTimeType":"pre","actualEps":-1.06},{"market":"US","date":"2025-03-21","symbol":"SNGX","fiscalQuarterEnding":"2024/12","expectedEps":-0.95,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742529600000,"reportTimeType":"pre","actualEps":-1.14},{"market":"US","date":"2024-11-08","symbol":"SNGX","fiscalQuarterEnding":"2024/09","expectedEps":-1.09,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731042000000,"reportTimeType":"pre","actualEps":-0.78}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SNGX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SNGX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1752987600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SNGX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SNGX","date":"2025-12-09","current":-0.37687,"percent":0.426483,"low":-5.464746,"twenty":-2.612754,"median":-1.246297,"eighty":-0.616672,"high":-0.277411,"avg":-1.606855,"sd":1.079906,"marketCap":15936085},"quantilePoints":[{"date":"2020-12-11","current":-4.570515,"twenty":-3.833505,"median":-3.035911,"eighty":-2.115839,"marketCap":68648754},{"date":"2020-12-18","current":-5.325643,"twenty":-3.84402,"median":-3.041386,"eighty":-2.116451,"marketCap":79990722},{"date":"2020-12-24","current":-2.662821,"twenty":-3.835838,"median":-3.035911,"eighty":-2.116451,"marketCap":39995360},{"date":"2020-12-31","current":-2.543591,"twenty":-3.825781,"median":-3.032517,"eighty":-2.116451,"marketCap":38204524},{"date":"2021-01-08","current":-2.821796,"twenty":-3.820118,"median":-3.031986,"eighty":-2.116451,"marketCap":42383144},{"date":"2021-01-15","current":-2.997624,"twenty":-3.820118,"median":-3.02874,"eighty":-2.116451,"marketCap":45024063},{"date":"2021-01-22","current":-3.605533,"twenty":-3.820118,"median":-3.02874,"eighty":-2.116451,"marketCap":54154817},{"date":"2021-01-29","current":-3.249173,"twenty":-3.822057,"median":-3.02874,"eighty":-2.116451,"marketCap":48802306},{"date":"2021-02-05","current":-3.458797,"twenty":-3.822057,"median":-3.02874,"eighty":-2.116451,"marketCap":51950841},{"date":"2021-02-12","current":-4.485954,"twenty":-3.822137,"median":-3.02874,"eighty":-2.116451,"marketCap":67378666},{"date":"2021-02-19","current":-3.982857,"twenty":-3.833505,"median":-3.030551,"eighty":-2.116451,"marketCap":59822181},{"date":"2021-02-26","current":-3.458797,"twenty":-3.833505,"median":-3.03163,"eighty":-2.116451,"marketCap":51950841},{"date":"2021-03-05","current":-3.207248,"twenty":-3.835264,"median":-3.031519,"eighty":-2.11619,"marketCap":48172598},{"date":"2021-03-12","current":-3.75227,"twenty":-3.835264,"median":-3.03243,"eighty":-2.11619,"marketCap":56358791},{"date":"2021-03-19","current":-3.75227,"twenty":-3.83612,"median":-3.040991,"eighty":-2.11619,"marketCap":56358791},{"date":"2021-03-26","current":-3.270135,"twenty":-3.835838,"median":-3.042299,"eighty":-2.116451,"marketCap":49117159},{"date":"2021-04-01","current":-3.529516,"twenty":-3.826467,"median":-3.042299,"eighty":-2.116451,"marketCap":62431916},{"date":"2021-04-09","current":-3.41639,"twenty":-3.822157,"median":-3.042299,"eighty":-2.11619,"marketCap":60430892},{"date":"2021-04-16","current":-2.963888,"twenty":-3.822157,"median":-3.041843,"eighty":-2.11619,"marketCap":52426802},{"date":"2021-04-23","current":-3.212764,"twenty":-3.822057,"median":-3.040991,"eighty":-2.11619,"marketCap":56829052},{"date":"2021-04-30","current":-3.258014,"twenty":-3.822057,"median":-3.040991,"eighty":-2.11619,"marketCap":57629461},{"date":"2021-05-07","current":-2.896013,"twenty":-3.808915,"median":-3.033651,"eighty":-2.11619,"marketCap":51226187},{"date":"2021-05-14","current":-2.013634,"twenty":-3.807849,"median":-3.030979,"eighty":-2.11619,"marketCap":35618208},{"date":"2021-05-21","current":-3.342664,"twenty":-3.807849,"median":-3.034785,"eighty":-2.11619,"marketCap":41681899},{"date":"2021-05-28","current":-3.278382,"twenty":-3.807849,"median":-3.042299,"eighty":-2.11619,"marketCap":40880324},{"date":"2021-06-04","current":-3.471227,"twenty":-3.807849,"median":-3.047644,"eighty":-2.11619,"marketCap":43285047},{"date":"2021-06-11","current":-3.792638,"twenty":-3.808915,"median":-3.051016,"eighty":-2.11619,"marketCap":47292924},{"date":"2021-06-18","current":-3.599792,"twenty":-3.815158,"median":-3.058506,"eighty":-2.11619,"marketCap":44888198},{"date":"2021-06-25","current":-3.696215,"twenty":-3.815158,"median":-3.073824,"eighty":-2.11619,"marketCap":46090561},{"date":"2021-07-02","current":-3.342664,"twenty":-3.814599,"median":-3.085535,"eighty":-2.11619,"marketCap":41681899},{"date":"2021-07-09","current":-3.406946,"twenty":-3.820677,"median":-3.087545,"eighty":-2.11619,"marketCap":42483474},{"date":"2021-07-16","current":-3.149818,"twenty":-3.820677,"median":-3.091406,"eighty":-2.11619,"marketCap":39277173},{"date":"2021-07-23","current":-3.10032,"twenty":-3.820677,"median":-3.101159,"eighty":-2.11619,"marketCap":38659960},{"date":"2021-07-30","current":-3.063037,"twenty":-3.820677,"median":-3.120558,"eighty":-2.11619,"marketCap":38195046},{"date":"2021-08-06","current":-3.2141,"twenty":-3.820677,"median":-3.123123,"eighty":-2.11619,"marketCap":40078748},{"date":"2021-08-13","current":-3.271976,"twenty":-3.820677,"median":-3.12497,"eighty":-2.116451,"marketCap":37922108},{"date":"2021-08-20","current":-3.183049,"twenty":-3.820677,"median":-3.127219,"eighty":-2.128852,"marketCap":36891443},{"date":"2021-08-27","current":-3.529416,"twenty":-3.819297,"median":-3.140414,"eighty":-2.139444,"marketCap":40905829},{"date":"2021-09-03","current":-3.806233,"twenty":-3.819297,"median":-3.149818,"eighty":-2.140169,"marketCap":44114128},{"date":"2021-09-10","current":-4.013846,"twenty":-3.822057,"median":-3.152361,"eighty":-2.145333,"marketCap":46520354},{"date":"2021-09-17","current":-3.737029,"twenty":-3.822117,"median":-3.16435,"eighty":-2.145333,"marketCap":43312052},{"date":"2021-09-24","current":-3.546717,"twenty":-3.822117,"median":-3.180179,"eighty":-2.145333,"marketCap":41106347},{"date":"2021-10-01","current":-3.633222,"twenty":-3.822117,"median":-3.181533,"eighty":-2.145333,"marketCap":42108942},{"date":"2021-10-08","current":-3.59862,"twenty":-3.822117,"median":-3.189617,"eighty":-2.145333,"marketCap":41707904},{"date":"2021-10-15","current":-3.806233,"twenty":-3.822117,"median":-3.197852,"eighty":-2.150499,"marketCap":44114128},{"date":"2021-10-22","current":-3.494814,"twenty":-3.822117,"median":-3.211097,"eighty":-2.154035,"marketCap":40504791},{"date":"2021-10-29","current":-3.494814,"twenty":-3.822117,"median":-3.2141,"eighty":-2.161849,"marketCap":40504791},{"date":"2021-11-05","current":-3.42561,"twenty":-3.822117,"median":-3.220267,"eighty":-2.162699,"marketCap":39702715},{"date":"2021-11-12","current":-2.916544,"twenty":-3.822117,"median":-3.222002,"eighty":-2.170406,"marketCap":39044830},{"date":"2021-11-19","current":-2.741366,"twenty":-3.822117,"median":-3.218265,"eighty":-2.170406,"marketCap":36699653},{"date":"2021-11-26","current":-2.875872,"twenty":-3.822117,"median":-3.216049,"eighty":-2.170406,"marketCap":38500338},{"date":"2021-12-03","current":-2.562024,"twenty":-3.822117,"median":-3.2141,"eighty":-2.170406,"marketCap":34298742},{"date":"2021-12-10","current":-2.446092,"twenty":-3.822117,"median":-3.2141,"eighty":-2.170406,"marketCap":32746723},{"date":"2021-12-17","current":-2.394211,"twenty":-3.822117,"median":-3.211931,"eighty":-2.170406,"marketCap":32052174},{"date":"2021-12-23","current":-2.458582,"twenty":-3.822117,"median":-3.203637,"eighty":-2.170406,"marketCap":32913930},{"date":"2021-12-31","current":-2.114631,"twenty":-3.822117,"median":-3.191039,"eighty":-2.169084,"marketCap":28309324},{"date":"2022-01-07","current":-2.217909,"twenty":-3.822097,"median":-3.181959,"eighty":-2.166201,"marketCap":29691947},{"date":"2022-01-14","current":-2.069155,"twenty":-3.813481,"median":-3.181107,"eighty":-2.161849,"marketCap":27700521},{"date":"2022-01-21","current":-2.036489,"twenty":-3.810294,"median":-3.1662,"eighty":-2.161849,"marketCap":27263212},{"date":"2022-01-28","current":-1.97436,"twenty":-3.809605,"median":-3.158329,"eighty":-2.15359,"marketCap":26431467},{"date":"2022-02-04","current":-1.986209,"twenty":-3.809605,"median":-3.149818,"eighty":-2.148285,"marketCap":26590099},{"date":"2022-02-11","current":-2.014712,"twenty":-3.809605,"median":-3.144477,"eighty":-2.14007,"marketCap":26971673},{"date":"2022-02-18","current":-2.17772,"twenty":-3.809605,"median":-3.132783,"eighty":-2.139444,"marketCap":29153928},{"date":"2022-02-25","current":-2.306142,"twenty":-3.809605,"median":-3.129679,"eighty":-2.139444,"marketCap":30873154},{"date":"2022-03-04","current":-2.145054,"twenty":-3.809605,"median":-3.129679,"eighty":-2.138219,"marketCap":28716619},{"date":"2022-03-11","current":-2.312226,"twenty":-3.809605,"median":-3.124184,"eighty":-2.138219,"marketCap":30954613},{"date":"2022-03-18","current":-2.222556,"twenty":-3.806233,"median":-3.11997,"eighty":-2.138219,"marketCap":29754157},{"date":"2022-03-25","current":-2.309344,"twenty":-3.806233,"median":-3.105034,"eighty":-2.138219,"marketCap":30916027},{"date":"2022-04-01","current":-2.532554,"twenty":-3.806233,"median":-3.105034,"eighty":-2.139763,"marketCap":31786020},{"date":"2022-04-08","current":-2.529132,"twenty":-3.806233,"median":-3.105034,"eighty":-2.14463,"marketCap":31743066},{"date":"2022-04-14","current":-2.481219,"twenty":-3.806233,"median":-3.105034,"eighty":-2.150636,"marketCap":31141708},{"date":"2022-04-22","current":-2.102362,"twenty":-3.806233,"median":-3.105034,"eighty":-2.152006,"marketCap":26386692},{"date":"2022-04-29","current":-1.80975,"twenty":-3.806233,"median":-3.105034,"eighty":-2.14463,"marketCap":22714119},{"date":"2022-05-06","current":-1.772104,"twenty":-3.806233,"median":-3.105034,"eighty":-2.142794,"marketCap":22241624},{"date":"2022-05-13","current":-1.178605,"twenty":-3.806233,"median":-3.100739,"eighty":-2.140196,"marketCap":17133992},{"date":"2022-05-20","current":-1.543144,"twenty":-3.806233,"median":-3.091406,"eighty":-2.139444,"marketCap":22433476},{"date":"2022-05-27","current":-1.77383,"twenty":-3.806233,"median":-3.089475,"eighty":-2.129342,"marketCap":25787088},{"date":"2022-06-03","current":-1.514419,"twenty":-3.806233,"median":-3.087545,"eighty":-2.119815,"marketCap":22015888},{"date":"2022-06-10","current":-1.776792,"twenty":-3.806233,"median":-3.087545,"eighty":-2.115527,"marketCap":25830138},{"date":"2022-06-17","current":-1.687952,"twenty":-3.806233,"median":-3.087545,"eighty":-2.100887,"marketCap":24538630},{"date":"2022-06-24","current":-1.617473,"twenty":-3.806233,"median":-3.087545,"eighty":-2.092935,"marketCap":23514034},{"date":"2022-07-01","current":-1.719934,"twenty":-3.806233,"median":-3.087545,"eighty":-2.086976,"marketCap":25003573},{"date":"2022-07-08","current":-1.762281,"twenty":-3.806233,"median":-3.087545,"eighty":-2.078536,"marketCap":25619192},{"date":"2022-07-15","current":-2.025543,"twenty":-3.806233,"median":-3.087545,"eighty":-2.0727,"marketCap":29446357},{"date":"2022-07-22","current":-2.259783,"twenty":-3.806233,"median":-3.077014,"eighty":-2.0727,"marketCap":32851632},{"date":"2022-07-29","current":-2.592339,"twenty":-3.806233,"median":-3.070415,"eighty":-2.0727,"marketCap":37686173},{"date":"2022-08-05","current":-2.679994,"twenty":-3.806233,"median":-3.070415,"eighty":-2.0727,"marketCap":38960460},{"date":"2022-08-12","current":-2.539174,"twenty":-3.806233,"median":-3.068833,"eighty":-2.0727,"marketCap":38156702},{"date":"2022-08-19","current":-2.380834,"twenty":-3.793261,"median":-3.057725,"eighty":-2.0727,"marketCap":35777295},{"date":"2022-08-26","current":-2.280438,"twenty":-3.77381,"median":-3.037933,"eighty":-2.0727,"marketCap":34268616},{"date":"2022-09-02","current":-2.065302,"twenty":-3.75227,"median":-3.012696,"eighty":-2.072608,"marketCap":31035726},{"date":"2022-09-09","current":-1.986419,"twenty":-3.744873,"median":-2.99389,"eighty":-2.068643,"marketCap":29850333},{"date":"2022-09-16","current":-1.921878,"twenty":-3.736351,"median":-2.972351,"eighty":-2.06071,"marketCap":28880466},{"date":"2022-09-23","current":-1.455464,"twenty":-3.71974,"median":-2.963888,"eighty":-2.050413,"marketCap":21871566},{"date":"2022-09-30","current":-1.252663,"twenty":-3.703324,"median":-2.929273,"eighty":-2.049272,"marketCap":18824029},{"date":"2022-10-07","current":-1.641628,"twenty":-3.69525,"median":-2.907735,"eighty":-2.046565,"marketCap":24669091},{"date":"2022-10-14","current":-1.686663,"twenty":-3.686342,"median":-2.894033,"eighty":-2.042346,"marketCap":25345843},{"date":"2022-10-21","current":-1.804558,"twenty":-3.668494,"median":-2.865205,"eighty":-2.037717,"marketCap":27117466},{"date":"2022-10-28","current":-2.007933,"twenty":-3.667825,"median":-2.841668,"eighty":-2.029514,"marketCap":30173622},{"date":"2022-11-04","current":-1.893481,"twenty":-3.66653,"median":-2.8149,"eighty":-2.026959,"marketCap":28453728},{"date":"2022-11-11","current":-2.05165,"twenty":-3.663597,"median":-2.797124,"eighty":-2.021049,"marketCap":30259092},{"date":"2022-11-18","current":-1.905104,"twenty":-3.648917,"median":-2.778014,"eighty":-2.01711,"marketCap":28097730},{"date":"2022-11-25","current":-1.699939,"twenty":-3.641768,"median":-2.743928,"eighty":-2.014281,"marketCap":25071819},{"date":"2022-12-02","current":-1.64132,"twenty":-3.633222,"median":-2.735277,"eighty":-2.004814,"marketCap":24207273},{"date":"2022-12-09","current":-1.533755,"twenty":-3.633222,"median":-2.711283,"eighty":-1.996265,"marketCap":22620834},{"date":"2022-12-16","current":-1.846485,"twenty":-3.633222,"median":-2.682693,"eighty":-1.984215,"marketCap":27233184},{"date":"2022-12-23","current":-1.891329,"twenty":-3.633222,"median":-2.662821,"eighty":-1.97859,"marketCap":27894562},{"date":"2022-12-30","current":-1.32478,"twenty":-3.633222,"median":-2.64295,"eighty":-1.974296,"marketCap":19538728},{"date":"2023-01-06","current":-1.410357,"twenty":-3.630477,"median":-2.626074,"eighty":-1.970255,"marketCap":20800882},{"date":"2023-01-13","current":-1.377155,"twenty":-3.619207,"median":-2.596781,"eighty":-1.964148,"marketCap":20311194},{"date":"2023-01-20","current":-1.469416,"twenty":-3.619207,"median":-2.584653,"eighty":-1.961265,"marketCap":21671919},{"date":"2023-01-27","current":-1.409182,"twenty":-3.619207,"median":-2.562024,"eighty":-1.955717,"marketCap":20783547},{"date":"2023-02-03","current":-1.351886,"twenty":-3.615611,"median":-2.546439,"eighty":-1.950333,"marketCap":19938511},{"date":"2023-02-10","current":-1.047974,"twenty":-3.615611,"median":-2.539174,"eighty":-1.93629,"marketCap":15456214},{"date":"2023-02-17","current":-0.812914,"twenty":-3.615611,"median":-2.519549,"eighty":-1.920521,"marketCap":11989399},{"date":"2023-02-24","current":-0.744355,"twenty":-3.615611,"median":-2.50894,"eighty":-1.916691,"marketCap":10978245},{"date":"2023-03-03","current":-0.579814,"twenty":-3.615611,"median":-2.50315,"eighty":-1.905104,"marketCap":8551475},{"date":"2023-03-10","current":-0.628784,"twenty":-3.615611,"median":-2.498294,"eighty":-1.893481,"marketCap":9273728},{"date":"2023-03-17","current":-0.45249,"twenty":-3.615611,"median":-2.494874,"eighty":-1.873469,"marketCap":6673617},{"date":"2023-03-24","current":-0.360425,"twenty":-3.615611,"median":-2.490459,"eighty":-1.864593,"marketCap":5315782},{"date":"2023-03-31","current":-0.385889,"twenty":-3.614644,"median":-2.487664,"eighty":-1.852184,"marketCap":5691353},{"date":"2023-04-06","current":-0.368498,"twenty":-3.614644,"median":-2.487664,"eighty":-1.838884,"marketCap":5084661},{"date":"2023-04-14","current":-0.343373,"twenty":-3.615611,"median":-2.488267,"eighty":-1.81823,"marketCap":4737979},{"date":"2023-04-21","current":-0.311554,"twenty":-3.615611,"median":-2.488267,"eighty":-1.806924,"marketCap":4298921},{"date":"2023-04-28","current":-0.311554,"twenty":-3.615611,"median":-2.488267,"eighty":-1.796476,"marketCap":4298921},{"date":"2023-05-05","current":-0.486536,"twenty":-3.615611,"median":-2.488267,"eighty":-1.780665,"marketCap":6713384},{"date":"2023-05-12","current":-0.530952,"twenty":-3.615611,"median":-2.488267,"eighty":-1.774785,"marketCap":7326252},{"date":"2023-05-19","current":-0.450777,"twenty":-3.615611,"median":-2.488267,"eighty":-1.773356,"marketCap":4731101},{"date":"2023-05-26","current":-0.548639,"twenty":-3.615611,"median":-2.488267,"eighty":-1.762981,"marketCap":5758198},{"date":"2023-06-02","current":-0.556758,"twenty":-3.615611,"median":-2.488267,"eighty":-1.761231,"marketCap":5843414},{"date":"2023-06-09","current":-0.568435,"twenty":-3.615611,"median":-2.488267,"eighty":-1.758431,"marketCap":5965964},{"date":"2023-06-16","current":-0.553201,"twenty":-3.615611,"median":-2.488267,"eighty":-1.753075,"marketCap":5806081},{"date":"2023-06-23","current":-0.549104,"twenty":-3.616579,"median":-2.489363,"eighty":-1.755221,"marketCap":5763076},{"date":"2023-06-30","current":-0.549025,"twenty":-3.617546,"median":-2.490459,"eighty":-1.751843,"marketCap":5762256},{"date":"2023-07-07","current":-0.561243,"twenty":-3.617546,"median":-2.490459,"eighty":-1.719975,"marketCap":5890486},{"date":"2023-07-14","current":-0.534333,"twenty":-3.617546,"median":-2.490459,"eighty":-1.701031,"marketCap":5608055},{"date":"2023-07-21","current":-0.517398,"twenty":-3.617546,"median":-2.488267,"eighty":-1.696019,"marketCap":5430317},{"date":"2023-07-28","current":-0.487163,"twenty":-3.617546,"median":-2.48706,"eighty":-1.691433,"marketCap":5112988},{"date":"2023-08-04","current":-0.458552,"twenty":-3.617546,"median":-2.471478,"eighty":-1.68556,"marketCap":4812701},{"date":"2023-08-11","current":-0.492307,"twenty":-3.605533,"median":-2.464449,"eighty":-1.673383,"marketCap":5166973},{"date":"2023-08-18","current":-0.451047,"twenty":-3.604385,"median":-2.451581,"eighty":-1.658517,"marketCap":4733931},{"date":"2023-08-25","current":-0.474846,"twenty":-3.599792,"median":-2.429294,"eighty":-1.650503,"marketCap":4615829},{"date":"2023-09-01","current":-0.455119,"twenty":-3.59581,"median":-2.407007,"eighty":-1.641321,"marketCap":4424070},{"date":"2023-09-08","current":-0.515598,"twenty":-3.574766,"median":-2.401897,"eighty":-1.635487,"marketCap":5011970},{"date":"2023-09-15","current":-0.457243,"twenty":-3.566924,"median":-2.38362,"eighty":-1.627894,"marketCap":4444715},{"date":"2023-09-22","current":-0.50771,"twenty":-3.560315,"median":-2.374811,"eighty":-1.617598,"marketCap":4935296},{"date":"2023-09-29","current":-0.546143,"twenty":-3.551056,"median":-2.338167,"eighty":-1.605284,"marketCap":5308884},{"date":"2023-10-06","current":-0.576484,"twenty":-3.535509,"median":-2.330801,"eighty":-1.598066,"marketCap":5603822},{"date":"2023-10-13","current":-0.56637,"twenty":-3.529416,"median":-2.317858,"eighty":-1.582702,"marketCap":5505509},{"date":"2023-10-20","current":-0.529961,"twenty":-3.529416,"median":-2.309344,"eighty":-1.582674,"marketCap":5151583},{"date":"2023-10-27","current":-0.515296,"twenty":-3.529416,"median":-2.303676,"eighty":-1.573299,"marketCap":5009030},{"date":"2023-11-03","current":-0.488595,"twenty":-3.529416,"median":-2.295319,"eighty":-1.555321,"marketCap":4749485},{"date":"2023-11-10","current":-0.420732,"twenty":-3.529416,"median":-2.279706,"eighty":-1.52544,"marketCap":4089807},{"date":"2023-11-17","current":-0.49227,"twenty":-3.529416,"median":-2.266533,"eighty":-1.497359,"marketCap":3974781},{"date":"2023-11-24","current":-0.519915,"twenty":-3.529416,"median":-2.255719,"eighty":-1.484111,"marketCap":4197997},{"date":"2023-12-01","current":-1.259878,"twenty":-3.529416,"median":-2.246954,"eighty":-1.471408,"marketCap":10172748},{"date":"2023-12-08","current":-0.944716,"twenty":-3.529416,"median":-2.243626,"eighty":-1.458806,"marketCap":7628004},{"date":"2023-12-15","current":-0.760271,"twenty":-3.529416,"median":-2.242091,"eighty":-1.44978,"marketCap":6138727},{"date":"2023-12-22","current":-0.781479,"twenty":-3.529416,"median":-2.242091,"eighty":-1.42203,"marketCap":6309968},{"date":"2023-12-29","current":-0.878907,"twenty":-3.529416,"median":-2.242858,"eighty":-1.409887,"marketCap":7096639},{"date":"2024-01-05","current":-1.166178,"twenty":-3.529416,"median":-2.243626,"eighty":-1.402478,"marketCap":9416175},{"date":"2024-01-12","current":-1.113479,"twenty":-3.529416,"median":-2.241771,"eighty":-1.377273,"marketCap":8990667},{"date":"2024-01-19","current":-0.798188,"twenty":-3.529416,"median":-2.240902,"eighty":-1.367144,"marketCap":6444885},{"date":"2024-01-26","current":-0.76477,"twenty":-3.529416,"median":-2.232464,"eighty":-1.350711,"marketCap":6175051},{"date":"2024-02-02","current":-0.861041,"twenty":-3.529416,"median":-2.232464,"eighty":-1.323591,"marketCap":6952381},{"date":"2024-02-09","current":-0.832892,"twenty":-3.529416,"median":-2.232464,"eighty":-1.284479,"marketCap":6725098},{"date":"2024-02-16","current":-0.935719,"twenty":-3.529416,"median":-2.232464,"eighty":-1.19338,"marketCap":7555357},{"date":"2024-02-23","current":-0.96014,"twenty":-3.529416,"median":-2.232464,"eighty":-1.170061,"marketCap":7752543},{"date":"2024-03-01","current":-0.937004,"twenty":-3.529416,"median":-2.232314,"eighty":-1.094071,"marketCap":7565735},{"date":"2024-03-08","current":-1.015409,"twenty":-3.529416,"median":-2.232314,"eighty":-1.04266,"marketCap":8198808},{"date":"2024-03-15","current":-0.818497,"twenty":-3.529416,"median":-2.232314,"eighty":-0.985743,"marketCap":6608861},{"date":"2024-03-22","current":-1.096879,"twenty":-3.529416,"median":-2.231918,"eighty":-0.985743,"marketCap":6735639},{"date":"2024-03-28","current":-1.040493,"twenty":-3.529416,"median":-2.231918,"eighty":-0.985743,"marketCap":6389385},{"date":"2024-04-05","current":-0.805692,"twenty":-3.529416,"median":-2.232163,"eighty":-0.951971,"marketCap":4947537},{"date":"2024-04-12","current":-0.666183,"twenty":-3.529416,"median":-2.232163,"eighty":-0.937467,"marketCap":4090848},{"date":"2024-04-19","current":-0.746049,"twenty":-3.529416,"median":-2.232163,"eighty":-0.925458,"marketCap":4581287},{"date":"2024-04-26","current":-0.990316,"twenty":-3.529416,"median":-2.231918,"eighty":-0.92158,"marketCap":6081264},{"date":"2024-05-03","current":-0.938133,"twenty":-3.529416,"median":-2.231918,"eighty":-0.914511,"marketCap":5760823},{"date":"2024-05-10","current":-0.941612,"twenty":-3.529416,"median":-2.231918,"eighty":-0.914511,"marketCap":5782185},{"date":"2024-05-17","current":-0.792348,"twenty":-3.529416,"median":-2.231918,"eighty":-0.90316,"marketCap":5554316},{"date":"2024-05-24","current":-0.729366,"twenty":-3.529416,"median":-2.231918,"eighty":-0.885025,"marketCap":5112819},{"date":"2024-05-31","current":-0.711081,"twenty":-3.529416,"median":-2.231918,"eighty":-0.868111,"marketCap":4984642},{"date":"2024-06-07","current":-0.584609,"twenty":-3.529416,"median":-2.231918,"eighty":-0.841478,"marketCap":4098079},{"date":"2024-06-14","current":-0.584609,"twenty":-3.529416,"median":-2.232163,"eighty":-0.825714,"marketCap":4098079},{"date":"2024-06-21","current":-0.5184,"twenty":-3.529416,"median":-2.232314,"eighty":-0.813414,"marketCap":3633959},{"date":"2024-06-28","current":-0.373304,"twenty":-3.529416,"median":-2.233626,"eighty":-0.808757,"marketCap":2616845},{"date":"2024-07-05","current":-0.318365,"twenty":-3.529416,"median":-2.233626,"eighty":-0.804561,"marketCap":2231725},{"date":"2024-07-12","current":-1.077653,"twenty":-3.529416,"median":-2.233626,"eighty":-0.801249,"marketCap":7554290},{"date":"2024-07-15","current":-1.046662,"twenty":-3.529416,"median":-2.233626,"eighty":-0.801249,"marketCap":7337043},{"date":"2024-08-02","current":-0.618418,"twenty":-3.535509,"median":-2.215749,"eighty":-0.797123,"marketCap":4335076},{"date":"2024-08-09","current":-0.442331,"twenty":-3.535509,"median":-2.205592,"eighty":-0.792348,"marketCap":3100715},{"date":"2024-08-16","current":-1.081532,"twenty":-3.535509,"median":-2.189844,"eighty":-0.792348,"marketCap":7616606},{"date":"2024-08-23","current":-1.372962,"twenty":-3.535509,"median":-2.17772,"eighty":-0.792348,"marketCap":9668985},{"date":"2024-08-30","current":-1.058865,"twenty":-3.535509,"median":-2.174327,"eighty":-0.792348,"marketCap":7456976},{"date":"2024-09-06","current":-1.343819,"twenty":-3.535509,"median":-2.166303,"eighty":-0.792348,"marketCap":9463747},{"date":"2024-09-13","current":-1.110675,"twenty":-3.535509,"median":-2.161246,"eighty":-0.792348,"marketCap":7821844},{"date":"2024-09-20","current":-1.240199,"twenty":-3.535509,"median":-2.156951,"eighty":-0.792348,"marketCap":8734012},{"date":"2024-09-27","current":-1.246676,"twenty":-3.535509,"median":-2.145374,"eighty":-0.792348,"marketCap":8779620},{"date":"2024-10-04","current":-1.279057,"twenty":-3.535509,"median":-2.13956,"eighty":-0.792348,"marketCap":9007662},{"date":"2024-10-11","current":-1.292009,"twenty":-3.535509,"median":-2.13101,"eighty":-0.792348,"marketCap":9098879},{"date":"2024-10-18","current":-1.175437,"twenty":-3.535509,"median":-2.12822,"eighty":-0.792348,"marketCap":8277928},{"date":"2024-10-25","current":-1.20458,"twenty":-3.535509,"median":-2.123577,"eighty":-0.792348,"marketCap":8483166},{"date":"2024-10-31","current":-1.207818,"twenty":-3.535509,"median":-2.107658,"eighty":-0.792348,"marketCap":8505970},{"date":"2024-11-08","current":-1.123627,"twenty":-3.535509,"median":-2.074279,"eighty":-0.792348,"marketCap":7913060},{"date":"2024-11-15","current":-1.300862,"twenty":-3.535509,"median":-2.067722,"eighty":-0.792348,"marketCap":9234956},{"date":"2024-11-22","current":-1.187744,"twenty":-3.535509,"median":-2.067722,"eighty":-0.792348,"marketCap":8431916},{"date":"2024-11-29","current":-1.184209,"twenty":-3.535509,"median":-2.049939,"eighty":-0.792348,"marketCap":8406821},{"date":"2024-12-06","current":-1.131184,"twenty":-3.535509,"median":-2.033927,"eighty":-0.792348,"marketCap":8030396},{"date":"2024-12-13","current":-1.170069,"twenty":-3.535509,"median":-2.017112,"eighty":-0.792348,"marketCap":8306441},{"date":"2024-12-20","current":-1.088765,"twenty":-3.535509,"median":-2.001581,"eighty":-0.792348,"marketCap":7729256},{"date":"2024-12-27","current":-1.021601,"twenty":-3.535509,"median":-1.986209,"eighty":-0.792348,"marketCap":7252452},{"date":"2025-01-03","current":-1.039276,"twenty":-3.535509,"median":-1.976601,"eighty":-0.792348,"marketCap":7377927},{"date":"2025-01-10","current":-1.155929,"twenty":-3.529416,"median":-1.97197,"eighty":-0.792348,"marketCap":8206061},{"date":"2025-01-17","current":-0.802434,"twenty":-3.523734,"median":-1.964077,"eighty":-0.792348,"marketCap":5696562},{"date":"2025-01-24","current":-0.887273,"twenty":-3.508918,"median":-1.953718,"eighty":-0.792348,"marketCap":6298842},{"date":"2025-01-31","current":-0.816574,"twenty":-3.487384,"median":-1.94499,"eighty":-0.792348,"marketCap":5796942},{"date":"2025-02-07","current":-0.830713,"twenty":-3.464081,"median":-1.928314,"eighty":-0.792348,"marketCap":5897322},{"date":"2025-02-14","current":-0.869598,"twenty":-3.460004,"median":-1.914564,"eighty":-0.792348,"marketCap":6173367},{"date":"2025-02-21","current":-0.862528,"twenty":-3.449367,"median":-1.905104,"eighty":-0.792348,"marketCap":6123177},{"date":"2025-02-28","current":-0.795364,"twenty":-3.435067,"median":-1.886817,"eighty":-0.792348,"marketCap":5646372},{"date":"2025-03-07","current":-0.823644,"twenty":-3.423562,"median":-1.846485,"eighty":-0.790373,"marketCap":5847132},{"date":"2025-03-14","current":-0.813039,"twenty":-3.41639,"median":-1.80975,"eighty":-0.790373,"marketCap":5771847},{"date":"2025-03-21","current":-0.841318,"twenty":-3.407348,"median":-1.782714,"eighty":-0.790373,"marketCap":5972607},{"date":"2025-03-28","current":-0.866528,"twenty":-3.405471,"median":-1.77383,"eighty":-0.790373,"marketCap":7163218},{"date":"2025-04-04","current":-0.794114,"twenty":-3.378355,"median":-1.754307,"eighty":-0.790373,"marketCap":6564600},{"date":"2025-04-11","current":-0.72147,"twenty":-3.370724,"median":-1.718749,"eighty":-0.782944,"marketCap":5964089},{"date":"2025-04-17","current":-0.786365,"twenty":-3.368231,"median":-1.700232,"eighty":-0.779049,"marketCap":6500542},{"date":"2025-04-25","current":-0.822629,"twenty":-3.349519,"median":-1.687952,"eighty":-0.778595,"marketCap":6800324},{"date":"2025-05-02","current":-0.732922,"twenty":-3.335701,"median":-1.677345,"eighty":-0.767341,"marketCap":6058757},{"date":"2025-05-09","current":-0.752009,"twenty":-3.318337,"median":-1.658339,"eighty":-0.75921,"marketCap":6216537},{"date":"2025-05-16","current":-0.625327,"twenty":-3.306695,"median":-1.64132,"eighty":-0.752009,"marketCap":5995645},{"date":"2025-05-23","current":-0.623044,"twenty":-3.300954,"median":-1.631589,"eighty":-0.744363,"marketCap":5973753},{"date":"2025-05-30","current":-0.653685,"twenty":-3.291097,"median":-1.613804,"eighty":-0.737916,"marketCap":6267544},{"date":"2025-06-06","current":-0.626449,"twenty":-3.282404,"median":-1.587127,"eighty":-0.732937,"marketCap":6006396},{"date":"2025-06-13","current":-0.626449,"twenty":-3.276897,"median":-1.572151,"eighty":-0.718851,"marketCap":6006396},{"date":"2025-06-20","current":-0.607723,"twenty":-3.27413,"median":-1.559154,"eighty":-0.711081,"marketCap":5826857},{"date":"2025-06-27","current":-0.466432,"twenty":-3.268842,"median":-1.519397,"eighty":-0.698758,"marketCap":4472154},{"date":"2025-07-03","current":-0.408553,"twenty":-3.257603,"median":-1.473383,"eighty":-0.664356,"marketCap":3917215},{"date":"2025-07-11","current":-0.432386,"twenty":-3.236874,"median":-1.452959,"eighty":-0.65419,"marketCap":4145719},{"date":"2025-07-18","current":-0.463027,"twenty":-3.217218,"median":-1.430621,"eighty":-0.643472,"marketCap":4439510},{"date":"2025-07-25","current":-0.473241,"twenty":-3.2141,"median":-1.408221,"eighty":-0.637343,"marketCap":4537440},{"date":"2025-08-01","current":-0.997551,"twenty":-3.188721,"median":-1.381754,"eighty":-0.627362,"marketCap":9564533},{"date":"2025-08-08","current":-1.120117,"twenty":-3.181107,"median":-1.370141,"eighty":-0.627362,"marketCap":10739698},{"date":"2025-08-15","current":-1.000956,"twenty":-3.164793,"median":-1.351886,"eighty":-0.627362,"marketCap":9597177},{"date":"2025-08-22","current":-1.389916,"twenty":-3.149818,"median":-1.351739,"eighty":-0.627362,"marketCap":14399515},{"date":"2025-08-29","current":-1.265816,"twenty":-3.133169,"median":-1.335619,"eighty":-0.627362,"marketCap":13113844},{"date":"2025-09-05","current":-1.257543,"twenty":-3.117677,"median":-1.322798,"eighty":-0.627006,"marketCap":13028132},{"date":"2025-09-12","current":-1.14999,"twenty":-3.103112,"median":-1.30595,"eighty":-0.627362,"marketCap":11913884},{"date":"2025-09-19","current":-1.141717,"twenty":-3.087143,"median":-1.297273,"eighty":-0.627362,"marketCap":11828173},{"date":"2025-09-26","current":-0.670138,"twenty":-3.067674,"median":-1.286016,"eighty":-0.627362,"marketCap":6942623},{"date":"2025-10-03","current":-0.529492,"twenty":-3.01938,"median":-1.275424,"eighty":-0.623501,"marketCap":5485529},{"date":"2025-10-10","current":-1.442653,"twenty":-2.995922,"median":-1.267432,"eighty":-0.616672,"marketCap":14945873},{"date":"2025-10-17","current":-1.249225,"twenty":-2.91443,"median":-1.264341,"eighty":-0.616672,"marketCap":12941957},{"date":"2025-10-24","current":-1.289522,"twenty":-2.875231,"median":-1.264341,"eighty":-0.616672,"marketCap":13359440},{"date":"2025-10-31","current":-1.216987,"twenty":-2.813038,"median":-1.258586,"eighty":-0.616672,"marketCap":12607971},{"date":"2025-11-07","current":-1.031618,"twenty":-2.781244,"median":-1.253152,"eighty":-0.616672,"marketCap":10687552},{"date":"2025-11-14","current":-1.245919,"twenty":-2.740725,"median":-1.250644,"eighty":-0.616672,"marketCap":13918859},{"date":"2025-11-21","current":-1.146607,"twenty":-2.677684,"median":-1.246297,"eighty":-0.616672,"marketCap":12809385},{"date":"2025-11-28","current":-1.435516,"twenty":-2.656351,"median":-1.246297,"eighty":-0.616672,"marketCap":16036946},{"date":"2025-12-05","current":-1.471629,"twenty":-2.625475,"median":-1.246297,"eighty":-0.616672,"marketCap":16440391},{"date":"2025-12-09","current":-1.426487,"twenty":-2.612754,"median":-1.246297,"eighty":-0.616672,"marketCap":15936085}],"updateTime":1765431460860},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SNGX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2589890136","title":"Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad","url":"https://stock-news.laohu8.com/highlight/detail?id=2589890136","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589890136?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:30","pubTimestamp":1764941400,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec.  05, 2025  (GLOBE NEWSWIRE) -- via BioMedWire: — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire (\"BMW\"), one of 75+ brands withinthe","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/05/3200703/0/en/Soligenix-Inc-NASDAQ-SNGX-Advancing-Rare-Disease-Therapies-Positioned-at-Pivotal-Crossroad.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NQmain","NVIW.SI","PSQ","TQQQ","SQQQ","QLD","BK4555","BK4604","SNGX","TM","USJW.SI",".IXIC","BK4099","USAW.SI","QID","BK4022","BK4585","BK4232","BK4139","BK4588","TSYW.SI","R","03160","MNQmain"],"gpt_icon":1},{"id":"2588413320","title":"Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space","url":"https://stock-news.laohu8.com/highlight/detail?id=2588413320","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588413320?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:30","pubTimestamp":1764768600,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec.  03, 2025  (GLOBE NEWSWIRE) -- via BioMedWire: — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire (\"BMW\"), one of 75+ brands withinthe","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/03/3198880/0/en/Soligenix-Inc-NASDAQ-SNGX-Innovative-Platform-Provides-Novel-Treatment-for-Underserved-CTCL-Space.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QID","NVIW.SI","BK4099","BK4555","PSQ","QLD","SNGX","BK4139","USAW.SI","USJW.SI","03160","MNQmain","BK4232","R","BK4604","TSYW.SI","SQQQ",".IXIC","TM","TQQQ","BK4585","NQmain","BK4588","BK4022"],"gpt_icon":1},{"id":"2586491196","title":"Soligenix Inc. unveils pipeline progress and rare disease treatment strategies in new corporate presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2586491196","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586491196?lang=en_us&edition=fundamental","pubTime":"2025-11-25 01:52","pubTimestamp":1764006762,"startTime":"0","endTime":"0","summary":"Soligenix Inc. has released a corporate presentation outlining updates across its pipeline for rare disease treatments and public health solutions. The company highlighted progress in its Specialized BioTherapeutics segment, including the ongoing Phase 2a clinical study of SGX302 for mild-to-moderate psoriasis, with clinical success observed in two of four patients in Cohort 2. The presentation also noted the completion of a Phase 2a proof-of-concept study for SGX945 in treating aphthous ulcers in Behet's Disease, demonstrating biological efficacy and safety. Within its Public Health Solutions segment, Soligenix reported continued development of its vaccine candidates for ricin toxin, filoviruses such as Ebola and Marburg, and COVID-19, supported by ongoing government funding and collaborations. The pipeline includes multiple fast track and orphan designated products, with several candidates advancing through late-stage clinical studies and regulatory discussions. You can access the fu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL5vYRK0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2584946056","title":"Soligenix completes enrollment of patients for Phase 3 study evaluating HyBryte","url":"https://stock-news.laohu8.com/highlight/detail?id=2584946056","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584946056?lang=en_us&edition=fundamental","pubTime":"2025-11-19 20:35","pubTimestamp":1763555743,"startTime":"0","endTime":"0","summary":"Soligenix (SNGX) announced that it has completed the planned enrollment of 50 patients necessary for the interim analysis in its 80 patient confirm...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/soligenix-completes-enrollment-of-patients-for-phase-3-study-evaluating-hybryte-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/soligenix-completes-enrollment-of-patients-for-phase-3-study-evaluating-hybryte-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2584946131","title":"Soligenix Reaches Interim Enrollment Milestone in Phase 3 HyBryte Trial for CTCL","url":"https://stock-news.laohu8.com/highlight/detail?id=2584946131","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584946131?lang=en_us&edition=fundamental","pubTime":"2025-11-19 20:30","pubTimestamp":1763555441,"startTime":"0","endTime":"0","summary":"Soligenix Inc. has announced the completion of patient enrollment for the planned interim analysis in its confirmatory Phase 3 clinical trial of HyBryte  for the treatment of cutaneous T-cell lymphoma . The trial, known as FLASH2, has enrolled 50 out of a total 80 patients, reaching a key milestone for the interim analysis, which is scheduled to occur in the second quarter of 2026. The company reports that the overall blinded study response rate to date is 48%, exceeding the initial estimate of 25%. Topline results from the study are expected in the second half of 2026. Results from this trial have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL6LSLPH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2584946911","title":"Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of Hybryte™ for the Treatment of Cutaneous T-Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2584946911","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584946911?lang=en_us&edition=fundamental","pubTime":"2025-11-19 20:30","pubTimestamp":1763555416,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nFWN3WV10H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2584965976","title":"Soligenix Regains Nasdaq Compliance After Equity Shortfall","url":"https://stock-news.laohu8.com/highlight/detail?id=2584965976","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584965976?lang=en_us&edition=fundamental","pubTime":"2025-11-19 05:06","pubTimestamp":1763499962,"startTime":"0","endTime":"0","summary":"Soligenix Inc. announced that it has resolved a recent regulatory issue concerning its listing on the Nasdaq Capital Market. The company previously received notice from Nasdaq that it was not in compliance with the minimum stockholders' equity requirement of $2.5 million. However, Soligenix reported stockholders' equity of $7.6 million in its latest quarterly report, surpassing the required threshold. Nasdaq has confirmed that Soligenix has regained compliance and the matter is now closed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commis","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL9ZSMJ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2581000480","title":"Biopharma firm Soligenix's Q3 net loss widens on increased R&D spends","url":"https://stock-news.laohu8.com/highlight/detail?id=2581000480","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581000480?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:40","pubTimestamp":1762519253,"startTime":"0","endTime":"0","summary":"Biopharma firm Soligenix's Q3 net loss widens on increased R&D spendsOverviewSoligenix Q3 net loss widens to $2.5 mln due to increased clinical trial expensesCompany reports no revenue for Q3 2025, sa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL1N3WJ0IB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2581554000","title":"Soligenix Reports Net Loss of $2.5 Million With No Revenue in Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2581554000","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581554000?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:31","pubTimestamp":1762518676,"startTime":"0","endTime":"0","summary":"Soligenix Inc. reported no revenue for the quarters ended September 30, 2025 and 2024. The company posted a net loss of $2.5 million, or $0.58 per share, for the third quarter of 2025, compared to a net loss of $1.7 million, or $0.78 per share, for the same period in 2024. The increase in net loss was attributed to higher operating expenses related to clinical trials, decreased interest income, and the absence of a CARES Act employee retention credit received in the previous year. As of September 30, 2025, Soligenix held approximately $10.5 million in cash, which is expected to fund operations through 2026. Recent business developments include updates to the U.S. Medical Advisory Board for the Phase 3 development of HyBryte for CTCL and the FDA granting orphan drug designation to dusquetide for the treatment of Behet's Disease.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL23kVWl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2581000316","title":"Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2581000316","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581000316?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:30","pubTimestamp":1762518612,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nTUA9L6SH8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2581000606","title":"Soligenix Q3 EPS USD -0.58","url":"https://stock-news.laohu8.com/highlight/detail?id=2581000606","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581000606?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:30","pubTimestamp":1762518601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nPLX28EEAA:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2573954227","title":"Soligenix Announces Key Safety Milestone in Phase 3 FLASH2 Trial of HyBryte™ for Cutaneous T-Cell Lymphoma; Enrollment Progress on Track","url":"https://stock-news.laohu8.com/highlight/detail?id=2573954227","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573954227?lang=en_us&edition=fundamental","pubTime":"2025-10-07 19:30","pubTimestamp":1759836645,"startTime":"0","endTime":"0","summary":"Soligenix Announces Key Safety Milestone in Phase 3 FLASH2 Trial of HyBryte for Cutaneous T-Cell Lymphoma; Enrollment Progress on Track. Soligenix Inc. has announced progress in its confirmatory Phase 3 clinical trial of HyBryte  for the treatment of cutaneous T-cell lymphoma . The company reported that the first Data Monitoring Committee meeting found no safety concerns, confirming an acceptable safety profile consistent with previous studies. Patient enrollment for the FLASH2 study is proceeding as planned, with an enrollment update expected in the fourth quarter of 2025. A pre-specified blinded interim efficacy analysis is targeted for the first half of 2026, and topline results are anticipated in the second half of 2026. No efficacy results from this ongoing study have been presented yet.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nNDL2lm7Lh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2573954270","title":"Soligenix Inc - Flash2 Study Interim Efficacy Analysis Targeted for 1H2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2573954270","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573954270?lang=en_us&edition=fundamental","pubTime":"2025-10-07 19:30","pubTimestamp":1759836644,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nTUA7DMSQT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2573895478","title":"Soligenix Inc - Enrollment Update Remains on Track for 4Q2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2573895478","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573895478?lang=en_us&edition=fundamental","pubTime":"2025-10-07 19:30","pubTimestamp":1759836644,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nTUA7DMSQT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2573542899","title":"Soligenix Achieves Important Safety Milestone in Its Confirmatory Phase 3 Clinical Trial of Hybryte™ for the Treatment of Cutaneous T-Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2573542899","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573542899?lang=en_us&edition=fundamental","pubTime":"2025-10-07 19:30","pubTimestamp":1759836644,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nTUA7DMSQT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2572252684","title":"Soligenix Inc. Chairman, CEO and President Christopher J. Schaber Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2572252684","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572252684?lang=en_us&edition=fundamental","pubTime":"2025-10-04 01:18","pubTimestamp":1759511932,"startTime":"0","endTime":"0","summary":"Christopher J. Schaber, Chairman, CEO, and President of Soligenix Inc., reported the acquisition of common shares of Soligenix Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nNDL3DShNy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2571341009","title":"Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2571341009","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571341009?lang=en_us&edition=fundamental","pubTime":"2025-09-30 19:30","pubTimestamp":1759231839,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nTUA341KZN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2571134487","title":"Soligenix Inc. Expands European Medical Advisory Board to Support HyBryte™ Phase 3 Trial and Regulatory Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2571134487","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571134487?lang=en_us&edition=fundamental","pubTime":"2025-09-30 19:30","pubTimestamp":1759231834,"startTime":"0","endTime":"0","summary":"Soligenix Inc. has expanded its European Medical Advisory Board to support the development of HyBryte for cutaneous T-cell lymphoma. The board now includes additional experts who will advise on the ongoing Phase 3 clinical trial and provide input on clinical and strategic matters as the company pursues marketing approvals in Europe.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief via PR Newswire  on September 30, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDL1Nvxgr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2571715368","title":"BRIEF-Soligenix Says On Sept 25, Entered Securities Purchase Agreement With Investors - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2571715368","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571715368?lang=en_us&edition=fundamental","pubTime":"2025-09-30 04:54","pubTimestamp":1759179241,"startTime":"0","endTime":"0","summary":"BRIEF-Soligenix Says On Sept 25, Entered Securities Purchase Agreement With Investors - SEC FilingSept 29  - Soligenix Inc SNGX.O:SOLIGENIX INC - ON SEPT 25, ENTERS SECURITIES PURCHASE AGREEMENT WITH INVESTORS - SEC FILINGSource text: [ID:n0001104659-25-094507]Further company coverage: SNGX.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nFWN3VG0GB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2571368813","title":"BRIEF-Soligenix Announces Closing Of $7.5 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2571368813","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571368813?lang=en_us&edition=fundamental","pubTime":"2025-09-30 04:32","pubTimestamp":1759177953,"startTime":"0","endTime":"0","summary":"BRIEF-Soligenix Announces Closing Of $7.5 Million Public OfferingSept 29 (Reuters) - Soligenix Inc SNGX.O:SOLIGENIX ANNOUNCES CLOSING OF $7.5 MILLION PUBLIC OFFERINGSource text: ID:nPn7ZqyXNaFurther company coverage: SNGX.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nTUA1SYKCH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNGX"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":58,"code":"91000000","status":"200"}]}}